The Role of Hyaluronan in Asherman’s Syndrome Therapy

J 2015

The Role of Hyaluronan in Asherman’s Syndrome Therapy

KRAJČOVIČOVÁ, Renáta; Robert HUDEČEK; Pavel VENTRUBA a Katarína SURGENTOVÁ

Základní údaje

Originální název

The Role of Hyaluronan in Asherman’s Syndrome Therapy

Autoři

KRAJČOVIČOVÁ, Renáta; Robert HUDEČEK; Pavel VENTRUBA a Katarína SURGENTOVÁ

Vydání

Journal of gynecologic surgery, Larchmont, Mary Ann Liebert Inc. 2015, 1042-4067

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.153 v roce 1999

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00084696

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Asherman´s syndrome; menstrual cycle; hormonal therapy; hyaluronan

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 12. 2015 17:11, Soňa Böhmová

Anotace

V originále

Prospective clinical evaluation comparing the therapy of Asherman’s syndrome in patients treated using hysteroscopic (HSK) adhesiolysis with insertion of 100% hyaluronic acid (HA) to a patient cohort with an inserted intrauterine device (IUD) and a control cohort. Design: Primary outcome—treatment for menstrual cycle problems. Secondary outcome—attainment of pregnancy after spontaneous conception within 1 year after the ending of hormonal therapy. Materials and Methods: Sixty patients treated from 1997 to 2014 for Asherman’s syndrome (in Stage II and III). Cohort A: Insertion of 100% HA (20 patients). Cohort B: Insertion of an IUD (18 patients). Cohort C: Without insertion of antiadhesion agent (22 patients). Primary and secondary goals were evaluated for all patients after a 3-month hormonal therapy. Results: The normal menstrual cycle was restored in 12 out of 20 patients in cohort A (60.0%), in 10 out of 18 patients in cohort B (55.5%), and 8 out of 22 patients in control cohort C (36.3%). A spontaneous pregnancy within 1 year after the end of the treatment was achieved by 14 out of 18 patients (77.7%) in cohort A, by 6 out of 10 patients (60.0%) in cohort B, and by 6 out of 14 patients (42.8%) in cohort C. Ten patients (55.5%) gave birth in cohort A, 4 patients (40.0%) in cohort B, and 4 patients (28.5%) in cohort C. Given the small number of the included patients, there was no statistically significant difference identified in any of the followed cohorts through the completed statistical analysis. Conclusion: Intrauterine insertion of hyaluronan after the completed HSK adhesiolysis enabled the recovery of the normal menstrual cycle for 60.0% of the patients and improved the implantation rate (77.7%) and take home baby rate (55.5%), compared to the group of patients with insertion IUD and with the control group. ( J GYNECOL SURG 31:250)

Citovat

KRAJČOVIČOVÁ, Renáta; Robert HUDEČEK; Pavel VENTRUBA a Katarína SURGENTOVÁ. The Role of Hyaluronan in Asherman’s Syndrome Therapy. Journal of gynecologic surgery. Larchmont: Mary Ann Liebert Inc., 2015, roč. 31, č. 5, s. 250-254. ISSN 1042-4067. Dostupné z: https://doi.org/10.1089/gyn.2014.0129.

@article{1317134,
   author = {Krajčovičová, Renáta and Hudeček, Robert and Ventruba, Pavel and Surgentová, Katarína},
   article_location = {Larchmont},
   article_number = {5},
   doi = {https://doi.org/10.1089/gyn.2014.0129},
   keywords = {Asherman´s syndrome; menstrual cycle; hormonal therapy; hyaluronan},
   language = {eng},
   issn = {1042-4067},
   journal = {Journal of gynecologic surgery},
   title = {The Role of Hyaluronan in Asherman’s Syndrome Therapy},
   volume = {31},
   year = {2015}
}

TY  - JOUR
ID  - 1317134
AU  - Krajčovičová, Renáta - Hudeček, Robert - Ventruba, Pavel - Surgentová, Katarína
PY  - 2015
TI  - The Role of Hyaluronan in Asherman’s Syndrome Therapy
JF  - Journal of gynecologic surgery
VL  - 31
IS  - 5
SP  - 250-254
EP  - 250-254
PB  - Mary Ann Liebert Inc.
SN  - 10424067
KW  - Asherman´s syndrome
KW  - menstrual cycle
KW  - hormonal therapy
KW  - hyaluronan
N2  - Prospective clinical evaluation comparing the therapy of Asherman’s syndrome in patients treated using hysteroscopic (HSK) adhesiolysis with insertion of 100% hyaluronic acid (HA) to a patient cohort with an inserted intrauterine device (IUD) and a control cohort. Design: Primary outcome—treatment for menstrual cycle problems. Secondary outcome—attainment of pregnancy after spontaneous conception within 1 year after the ending of hormonal therapy. Materials and Methods: Sixty patients treated from 1997 to 2014 for Asherman’s syndrome (in Stage II and III). Cohort A: Insertion of 100% HA (20 patients). Cohort B: Insertion of an IUD (18 patients). Cohort C: Without insertion of antiadhesion agent (22 patients). Primary and secondary goals were evaluated for all patients after a 3-month hormonal therapy. Results: The normal menstrual cycle was restored in 12 out of 20 patients in cohort A (60.0%), in 10 out of 18 patients in cohort B (55.5%), and 8 out of 22 patients in control cohort C (36.3%). A spontaneous pregnancy within 1 year after the end of the treatment was achieved by 14 out of 18 patients (77.7%) in cohort A, by 6 out of 10 patients (60.0%) in cohort B, and by 6 out of 14 patients (42.8%) in cohort C. Ten patients (55.5%) gave birth in cohort A, 4 patients (40.0%) in cohort B, and 4 patients (28.5%) in cohort C. Given the small number of the included patients, there was no statistically significant difference identified in any of the followed cohorts through the completed statistical analysis. Conclusion: Intrauterine insertion of hyaluronan after the completed HSK adhesiolysis enabled the recovery of the normal menstrual cycle for 60.0% of the patients and improved the implantation rate (77.7%) and take home baby rate (55.5%), compared to the group of patients with insertion IUD and with the control group. ( J GYNECOL SURG 31:250)
ER  -

KRAJČOVIČOVÁ, Renáta; Robert HUDEČEK; Pavel VENTRUBA a Katarína SURGENTOVÁ. The Role of Hyaluronan in Asherman’s Syndrome Therapy. \textit{Journal of gynecologic surgery}. Larchmont: Mary Ann Liebert Inc., 2015, roč.~31, č.~5, s.~250-254. ISSN~1042-4067. Dostupné z: https://doi.org/10.1089/gyn.2014.0129.

Přehled o publikaci